In this episode, Dr David Kerr continues his look at AI-driven CGM tools and the future of diabetes and metabolic health. He’s joined by Stanford W. Ascherman Professor of Genetics, Dr Michael Snyder to hear the latest on emerging technologies, and the shift towards integrative and personalised healthcare.They discuss:How AI and CGM technology is transforming diabetes and metabolic health managementAI identification of diabetes subtypes and personalised interventionsImpact of physical activity, sleep, and stress on glucose levels, as well as the emerging role of gut microbiome health in metabolic wellnessPotential of AI-driven tools for early intervention and improved health outcomesDr Snyder is the Stanford W. Ascherman Professor of Genetics and Director at the Stanford Center of Genomics and Personalized Medicine. He is a leader in the field of functional genomics and proteomics, and co-founder of many biotechnology companies, including Personalis, SensOmics, Qbio @qbioinc, January AI, Filtricine, Mirvie, and Protos.Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related